02206 新荷花
NEAUTUS
NEAUTUS
| Register Close | 2026/11/06 IPO Closing in 2 Days |
| Listing Date | 2026/11/11 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Sichuan Neautus Traditional Chinese Medicine Co., Ltd. is a large-scale traditional Chinese medicine (TCM) decoction-ready products provider in China. It rank second in China in terms of revenue from TCM decoction-ready products in 2025, capturing a market share of 0.4% , according to Frost & Sullivan.
--
The Group serves a broad range of institutional and retail clients - including hospitals and medical institutions, medical trading companies, pharmacies, pharmaceutical companies and, more recently, individual consumers - with traditional herbal preparations, wellness products and health management services. It offered over 770 types and 4,900 varieties of decoction-ready products, encompassing all major medicines used in TCM industry.
--
As of October 21, 2026，The Group's footprint extends across most provinces in Mainland China, as well as Hong Kong and Taiwan, and overseas into regions with strong TCM demand, such as Vietnam and Malaysia.
--
The Group's customers are mainly hospitals and medical institutions, medical trading companies, pharmacies, and pharmaceutical companies.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 50 |
GLOBAL OFFERING
| No. of Offer Shares | 6.52M H shares |
| No. of International Offer Shares | 5.87M H shares |
| No. of HK Offer Shares | 0.65M H shares |
| Offer Price | $40.20 - $50.55 |
| Stock Code | 2206 |
| Sponsor(s) | GF Capital (Hong Kong) Limited, ABCI Capital Limited |
| Underwriter(s) | GF Securities (Hong Kong) Brokerage Limited, ABCI Securities Company Limited, ICBC International Securities Limited, CMBC Securities Company Limited, uSmart Securities Limited, Tiger Brokers (HK) Global Limited, Zhongtai International Securities Limited, BOCI Asia Limited, SDIC Securities (Hong Kong) Limited |
TIME TABLE
| Application Period | Oct 30 (Fri) - noon, Nov 06 (Fri) |
| Price Determination Date | Nov 09 (Mon) |
| Result Announcement Date | On or before Nov 10 (Tue) |
| Result Announcement Date | On or before Nov 10 (Tue) |
| Result Announcement Date | On or before Nov 11 (Wed) |
| Dealings in Shares commence on | Nov 11, 2026. (Wed) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $40.20 - $50.55 |
| Capitalization (H Shares) | 2.62B - 3.29B |
| NAV / share ($) | $14.32 - $15.3 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 45.38, the net proceeds raised would be HKD 229.70M, of which |
| 33.4% : Expand production capacity of TCM decoction-ready products and enhancing production system with digital and intelligent capabilities |
| 29% : Sales and marketing activities |
| 11.4% : R&D of herbal wellness product tailored for individual customers; and establish to-C operating team |
| 10.2% : Building overseas sales channels in Vietnam and Malaysia |
| 6% : Strategic investments and potential acquisitions, with a focus on upstream TCM supply chain |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).